BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
| RegularNews read more...
Jan 04, 2023
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
| RegularNews read more...
Dec 30, 2022
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
| RegularNews read more...
Dec 13, 2022
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
| RegularNews read more...
Dec 09, 2022
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
| RegularNews read more...
Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
| RegularNews read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
| RegularNews read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
| RegularNews read more...
Nov 10, 2022
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
| RegularNews read more...
BeiGene to Present at Upcoming Investor Conferences
| RegularNews read more...
Nov 03, 2022
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
| RegularNews read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
| RegularNews read more...
Oct 26, 2022
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
| RegularNews read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
| RegularNews read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
| RegularNews read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
| RegularNews read more...
Sep 19, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
| RegularNews read more...
Sep 10, 2022
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
read more...
Sep 07, 2022
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
read more...
